Opinion Robin Toft is the Author of WE CAN™, the Executive Woman’s Guide to Career Advancement and founder and CEO of Toft Group Executive Search, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. In this article, she discusses the…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve unemployment rates in Mexico and how the pharmaceutical industry is getting involved.    The investment in human capital is an…

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…

Canada Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first article for PharmaBoardroom, Durhane explains the changing landscape for access to rare disease drugs in Canada and the actors involved in getting there.   The irony of the government processes, which, on…

Opinion Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical companies in Canada.    I’ve often wondered how things would be if Canada had steadily continued a path of biopharmaceutical discovery and commercialization after Banting and Best’s breakthrough in 1921, and what…

Canada As the healthcare industry continues to hype about AI’s potential to be transformative, it is important to remember that even software can harbour a certain amount of unconscious bias. Carla Smith champions transformational strategy, governance, and policy in the health sector, particularly in the areas of digital health and health IT.…

Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. In this article, Thompson outlines the country’s challenges to the healthcare system and the pharma…

Canada As the President of Innovative Medicines Canada, Pamela Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need when they need them. In her first article for PharmaBoardroom, Pamela calls for the regular assessment…

Canada The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The stem cell itself having been discovered in Canada, Marc LePage, president and CEO of Genome Canada, identifies great potential to attract more fundamental research into that domain in the future.…

Canada PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in Canadian pharma’s industry, regulatory affairs, reimbursement and pricing.     The Honourable Ginette Petitpas Taylor Minister of Health  The Honourable Ginette Petitpas Taylor was elected in October 2015 as a Member of Parliament in the riding of Moncton–Riverview–Dieppe. Ms…

Pharmacy Meghann Chilcott, Chief Technology/Marketing Officer at Benzer Pharmacy looks at current pharmaceutical service trends that aim to create a more perfect union among technology, medication delivery and patient care for independent pharmacists. The move toward automation is reducing the complexity faced by medical coders, with software acting as the go-between, providing…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…